Reaching women in Egypt

Article

Leadership and evidence-based approaches to alleviate the burden of blindness

The Al Noor Magrabi Foundation, which started its activities as an NGO dedicated to prevention of low vision and blindness in 2007, wanted to establish its activities on a scientific basis. Unfortunately, the last survey data it had available was done much earlier and so a data update was needed prior to embarking on any future initiatives.

In 2001 this was followed up by another study in Fayoum, a desert oasis. The sample size was 1500 inhabitants, 50% being children. The area involved encompassed 15 villages. These results demonstrated that active trachoma in children aged 1-15 ,greatly exceeded the WHO threshold (by up to 40%) and the prevalence of blindness among adults was around 11 %.

In terms of intervention, there were many different types. Some focused on female groups in Menoufiya, and this resulted in a 96% increase in knowledge and positive attitude towards using eye care. Another focused on school children that resulted in the inclusion of some health education messages in the primary school curriculum (grades 1 – 6).

Surgical and diagnostic training led to an upgrade in the capacity of the local service providers and included cataract and trichiasis surgeries, and other diagnostic and therapeutic aspects.

There was a mass distribution of Zithromax (azithromycin antibiotic) in one village to test application of the SAFE strategy, a series of interventions developed by WHO to control trachoma - Surgery, Antibiotics, Facial cleanliness and Environmental protection.

S – Lid Surgery for those at immediate risk of blindness

AAntibiotics to treat individual cases and reduced infection in a community

FFacial cleanliness and hygiene promotion to reduce transmission

EEnvironmental improvements

This helped to decrease active trachoma in children from 36% in Menoufiya to 12.5%. However, the prevalence increased to 20% after six months due to persistent bad hygiene factors where the E component wasn't implemented appropriately.

A successful pilot study of gender sensitive intervention, which was applied in two villages, resulted in a more extensive programme being carried out in the Samalout district of the Menia Governorate in Upper Egypt. The programme applied an integrated model for prevention of low vision and blindness through community health education, breaking down barriers, helping people to get assistance, and capacity building of the local providers.

Meanwhile, the Al Noor Magrabi Foundation continued conducting outreach caravans providing free cataract surgeries to deprived areas.

Recent studies of the outreach data, resulted in certain areas being selected for construction of vision centres, to serve as permanent outreach locations that provide examination, treatment and serve as referral centres to the charity hospital.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.